Open AccessPrognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma
Author(s) -
Yu Yongfeng,
Ding Zhengping,
Jian Hong,
Shen Lan,
Zhu Lei,
Lu Shun
Publication year - 2016
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.821
Subject(s) - adenocarcinoma , medicine , stage (stratigraphy) , pathological , oncology , lung , gastroenterology , lung cancer , mmp9 , matrix metalloproteinase , immunohistochemistry , pathology , cancer , biology , gene , downregulation and upregulation , paleontology , biochemistry
The clinical outcomes of patients with early‐stage non‐small cell lung cancer ( NSCLC ) have remained unsatisfactory after complete surgical resection. The objective of this study was to explore the prognostic value of matrix metalloproteinase 9 ( MMP 9) activity level in Chinese patients with stage I B lung adenocarcinoma. A sensitive and validated method was employed for determining the activity of MMP 9 in human lung adenocarcinoma cells in vitro. Then, the association was examined between the level of MMP 9 enzymatic activity and clinical outcomes. A total of 104 cases were stratified according to the IASLC / ATS / ERS classification scheme and activity of MMP 9 was analyzed by SensoLyte® assay kit. The results showed that the MMP 9 activity was the highest in solid predominant and micropapillary predominant subtypes, intermediate in acinar predominant and papillary predominant subtypes, and the lowest in lepidic predominant subtype. Multivariate analysis revealed that pathological subtype and activity of MMP 9 were independent prognostic factors for disease‐free survival ( DFS ), respectively ( P = 0.005 and 0.029). Significant relationship existed between enzyme activity of MMP 9 and prognosis. And the 30 months DFS of high‐ and low‐level MMP 9 activity tumors was 44.2% and 84.1% ( P < 0.0001), respectively. High‐level MMP 9 activity is correlated with aggressive tumor behaviors and poor clinical outcomes in early‐stage lung adenocarcinoma after complete resection.